Niva Bupa Receives IRDAI Show Cause Notice Following February 2025 Inspection

Niva Bupa Health Insurance Company Ltd has received a Show Cause Notice (SCN) from the Insurance Regulatory and Development Authority of India (IRDAI) following a regulatory inspection conducted in February 2025, the company informed stock exchanges.
According to the disclosure, IRDAI had carried out an inspection of the insurer earlier this year and subsequently shared its observations. Niva Bupa stated that it had “duly replied” to those initial observations.
On February 26, 2026, the regulator issued a Show Cause Notice concerning certain “business and operational aspects” of the company. The insurer said it is currently in the process of submitting a formal response to the notice.
Letter of Advice Issued
In addition to the SCN, IRDAI has issued a Letter of Advice highlighting specific compliance concerns. The communication flagged violations under various regulatory frameworks, including:
- IRDAI’s Master Circular on Health Insurance Business
- Master Circular on Protection of Policyholders’ Interest
- Master Circular on Corporate Governance
The company stated that it is taking necessary corrective measures as advised in the letter and is in the process of implementing the required compliance actions.
No Immediate Business Impact
Niva Bupa clarified that, at this stage, there is no impact on its financials, operations, or other business activities arising from the SCN or the Letter of Advice.
The Show Cause Notice relates to operational and business matters identified during the inspection, while the Letter of Advice calls for corrective and compliance-related steps on specified issues.
The insurer further confirmed that it has made the requisite disclosures under Regulation 30 and that the information provided is “true, correct and complete to the best of our knowledge and belief.”
Niva Bupa has requested stock exchanges to take the disclosure on record and reiterated that it is fully cooperating with the regulator and will respond to the notice in due course.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: Mar 2, 2026, 9:53 AM IST

Sachin Gupta
Sachin Gupta is a Content Writer with 6+ years of experience in the stock market, including global markets like the US, Canada, and Australia. At Angel One, Sachin specialises in creating financial content that simplifies complex market trends. Sachin holds a Master's in Commerce, specialising in Economics.
Know More- Aurobindo Pharma Share Price in Focus; USFDA Issues One Observation for Telangana Facility
- ACME Solar Share Price in Focus; Commissions 66.68 MW Solar and 300 MWh BESS Capacity in Rajasthan
- Apollo Micro Systems Share Price in Focus; Awarded Transfer of Technology for Semi Active Laser Homing System
- Bharat Forge Share Price in Focus; Partners with Pratt & Whitney Canada for DRDO’s HALE UAV Programme
- Infosys Share Price in Focus; Board to Consider September Quarter Results and Interim Dividend on October 23, 2026


